Results 81 to 90 of about 30,003 (287)

Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments

Clinical Pharmacology &Therapeutics, EarlyView.
Optimal dosing of oncological drugs is historically determined based on the “higher is better” paradigm. However, a paradigm shift in optimal dose selection has occurred in the development of new modalities, including molecularly targeted drugs, antibody drugs, and immunotherapies.
Hiroe Kitagaki, Kentaro Takeda, Kazuya Murai, Hideki Maeda   +3 more
wiley   +1 more source

Krónikus betegségek biológiai terápiájának alkalmazásával kapcsolatos gazdasági megfontolások = Economic consideration of the implementation of biotechnological therapies in chronic diseases [PDF]

, 2014
Disszertációmban egyes krónikus betegségekben alkalmazott biológiai terápiák gazdasági, pénzügyi és költségvetési hatásaival foglalkoztam. Célkitűzés: A biológiai gyógyszerek terápiás alkalmazásáról rendelkezésre álló tudás mind Magyarországon, mind a ...
Balogh, Orsolya
core   +1 more source

Biosimilars: an overview

Biosimilars, 2011
Bhupinder Singh Sekhon, Vikrant SalujaInstitute of Pharmacy, PCTE Group of Institutes, Near Baddowal Cantt. (Ludhiana), IndiaAbstract: “Biologics”, considered one of the fastest growing sectors of the pharmaceutical industry, has introduced many new treatments to life-threatening and rare illnesses.
Vikrant Saluja, Bhupinder Singh Sekhon
openaire   +4 more sources

Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model‐Based Meta‐Analysis

The Journal of Clinical Pharmacology, EarlyView.
Abstract This study utilized model‐based meta‐analysis (MBMA) to systematically assess the efficacy of methotrexate (MTX) monotherapy in improving rheumatoid arthritis (RA) symptoms and function. The assessment was based on indicators such as Disease Activity Score 28 (DAS28), Health Assessment Questionnaire, and American College of Rheumatology (ACR ...
Shengyang Chen, Yangrui Wu, Wei Huang, Jianxing Zhou, Zipeng Wei, Xuemei Wu   +5 more
wiley   +1 more source

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core  

The Future of Biosimilar Insulins [PDF]

Diabetes Spectrum, 2016
IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names ...
Kim, Anne Park, Bindler, Ross Jason
openaire   +3 more sources

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017

Акушерство, гинекология и репродукция, 2017
Within the framework of the 27th international conference «Reproductive technologies today and tomorrow», the first Russia-made follitropin alfa biosimilar for controlled ovarian stimulation in assisted reproductive technologies (ART) was presented.
I. I. Vorobiev, A. S. Semikhin, E. O. Golovina   +2 more
doaj   +1 more source

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Frontiers in Pharmacology, 2020
ObjectiveTo compare the market dynamics of biosimilar infliximab among four Organization for Economic Cooperation and Development (OECD) countries (UK, France, Japan, and Korea) where supply-side and demand-side policies varied greatly, given high and ...
Yujeong Kim, Hye-Young Kwon, Hye-Young Kwon, Brian Godman, Brian Godman, Brian Godman, Evelien Moorkens, Steven Simoens, SeungJin Bae   +8 more
doaj   +1 more source